Prof Karim Fizazi speaks to ecancer about the overall survival with abiraterone acetate plus prednisone for de novo metastatic castration-sensitive prostate cancer in the PEACE-1 trial.
Initially, he explains the rationale and methodology of the study.
Prof Fizazi then describes the results.
He concludes, that adding abiraterone to ADT plus docetaxel improves both rPFS and OS in mCSPC men, even when 84% of mCRPC men from the control arm receive an ASI.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.